1. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. (18th August 2021) Authors: Westphal, D.; Garzarolli, M.; Sergon, M.; Horak, P.; Hutter, B.; Becker, J.C.; Wiegel, M.; Maczey, E.; Blum, S.; Grosche‐Schlee, S.; Rütten, A.; Ugurel, S.; Stenzinger, A.; Glimm, H.; Aust, D.; Baretton, G.; Beissert, S.; Fröhling, S.; Redler, S.; Surowy, H. Journal: British journal of dermatology Issue: Volume 185:Number 6(2021) Page Start: 1186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. (1st December 2021) Authors: Westphal, D.; Garzarolli, M.; Sergon, M.; Horak, P.; Hutter, B.; Becker, J.C.; Wiegel, M.; Maczey, E.; Blum, S.; Grosche‐Schlee, S.; Rütten, A.; Ugurel, S.; Stenzinger, A.; Glimm, H.; Aust, D.; Baretton, G.; Beissert, S.; Fröhling, S.; Redler, S.; Surowy, H. Journal: British journal of dermatology Issue: Volume 185:Number 6(2021) Page Start: 1186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗